1-5 of 5
Rachel Wuerstlein
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P3-10-29: Start of SerMa – EUBREAST 5 (Seroma of the Mammary Gland) study (NCT05899387) - On the way to identify women at risk of developing seroma after mastectomy

Free
Nina Ditsch, Melitta Koepke, Nicole Pochert, Udo Jeschke, Mariella Schneider, Matthias Reiger, Claudia Traidl-Hoffmann, Angelika Mattmer, Shirin Hunstiger, Jacqueline Sagasser, Christian Dannecker, Mathis Wild, Christian Hinske, Sarah Friedrich, Steffi Hartmann, Henning Kahl, David Krug, Natalia Krawczyk, Kerstin Stemmer, Regina Fluhrer, Andreas Raue, Maria Luisa Gasparri, Roland Reitsamer, Justyna Jelinska, Güldeniz Cakmak, Eduard Bonci, Rachel Wuerstlein, Visnja Fink, Vesna Bjelic-Radisic, Marc Thill, Christoph Heitmann, Walter Weber, Annette Lebeau, Hans-Christian Kolberg, Toralf Reimer, Rosa di Micco, Jana de Boniface, Oreste Gentillini, Michael Untch, Maggie Banys-Paluchowski, Thorsten Kuehn
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P3-10-29.
https://doi.org/10.1158/1557-3265.SABCS24-P3-10-29
Published: 13 June 2025
View articletitled, Abstract P3-10-29: Start of SerMa – EUBREAST 5 (Seroma of the Mammary Gland) study (NCT05899387) - On the way to identify women at risk of developing seroma after mastectomy
Journal Articles

Abstract P1-10-04: First results of the WAVES study: Significant increase of patient satisfaction with longer initial consultation duration for breast cancer diagnosis

Free
Nina Ditsch, Melitta B. Koepke, Renate Haidinger, Brigitte Welter, Ute-Susann Albert, Christoph Aulmann, Traudl Baumgartner, Stefanie Corradini, Christian Dannecker, Johannes Ettl, Nadia Harbeck, Anne Herrmann-Johns, Christian Hinske, Marion Kiechle, Alkomiet Hasan, Klaus E. Jopp, Monika Klinkhammer-Schalke, Oliver Koelbl, Inaki Soto-Rey, Christoph Jung, Olaf Ortmann, Anna Rubeck, Gernot Müller, Verena Schmid, Frank Kramer, Franziska Feiler, Eva Schildmann, Stephan Seitz, Miriam Reicherts, Nadja Will, Achim Woeckel, Eva Schumacher-Wulff, Carl-Mathis Wild, Verina Wild, Carolin C. Hack, Rachel Wuerstlein, Susanne Kinnebrock, Miriam Kunz, Peter A. Fasching, Stefan Schiele, Matthias W. Beckmann
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P1-10-04.
https://doi.org/10.1158/1557-3265.SABCS24-P1-10-04
Published: 13 June 2025
View articletitled, Abstract P1-10-04: First results of the WAVES study: Significant increase of patient satisfaction with longer initial consultation duration for breast cancer diagnosis
Journal Articles

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial

Open Access
Monika Graeser, Oleg Gluz, Claudia Biehl, Daniel Ulbrich-Gebauer, Matthias Christgen, Jenci Palatty, Sherko Kuemmel, Eva-Maria Grischke, Doris Augustin, Michael Braun, Jochem Potenberg, Rachel Wuerstlein, Katja Krauss, Claudia Schumacher, Helmut Forstbauer, Toralf Reimer, Andrea Stefek, Hans Holger Fischer, Enrico Pelz, Christine zu Eulenburg, Ronald Kates, Hua Ni, Cornelia Kolberg-Liedtke, Friedrich Feuerhake, Hans Heinrich Kreipe, Ulrike Nitz, Nadia Harbeck
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (4): 805–814.
https://doi.org/10.1158/1078-0432.CCR-22-1587
Published: 16 February 2023
View articletitled, Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial
Open the PDF for Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial in another window
Includes: Supplementary data
Journal Articles

De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

Available to Purchase
Oleg Gluz, Ulrike Nitz, Cornelia Kolberg-Liedtke, Aleix Prat, Matthias Christgen, Sherko Kuemmel, Mohammad Parsa Mohammadian, Daniel Gebauer, Ronald Kates, Laia Paré, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Rachel Wuerstlein, Monika Graeser, Enrico Pelz, Katarzyna Jóźwiak, Christine zu Eulenburg, Hans Heinrich Kreipe, Nadia Harbeck, on behalf of the ADAPT TN investigators
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (22): 4995–5003.
https://doi.org/10.1158/1078-0432.CCR-22-0482
Published: 14 November 2022
View articletitled, De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial
Open the PDF for De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial in another window
Includes: Supplementary data
Journal Articles

A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2− Primary Breast Cancer

Free
John F.R. Robertson, Abigail Evans, Stephan Henschen, Cliona C. Kirwan, Ali Jahan, Laura M. Kenny, J. Michael Dixon, Peter Schmid, Ashutosh Kothari, Omar Mohamed, Peter A. Fasching, Kwok-Leung Cheung, Rachel Wuerstlein, Danielle Carroll, Teresa Klinowska, Justin P.O. Lindemann, Alexander MacDonald, Richard Mather, Rhiannon Maudsley, Michele Moschetta, Myria Nikolaou, Martine P. Roudier, Tinnu Sarvotham, Gaia Schiavon, Diansong Zhou, Li Zhou, Nadia Harbeck
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (16): 4242–4249.
https://doi.org/10.1158/1078-0432.CCR-19-3387
Published: 14 August 2020
View articletitled, A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2− Primary Breast Cancer
Open the PDF for A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2− Primary Breast Cancer in another window
Includes: Supplementary data